Marginum

⚡️BREAKING ⚡️ Marginum Ltd has initiated interventional clinical trials at the Tampere University Hospital in Finland. The first patient was successfully operated on utilising the HIVEN® device. To date, this is the first patient in the world treated with fluorescence-guided aspirate tissue monitoring technology. #rethinkingsurgery #marginum

We are proud to announce a significant regulatory milestone!💡 Marginum quality management system has been assessed and certified as meeting the requirements of ISO 13485:2016 and EN ISO 13485:2016. Safety and quality are non-negotiable in the medical device industry, and companies must ensure that best practices are implemented. We are committed to continuously improving the harmonisation, standardisation and simplification of our products, processes and procedures. ⚙️🔎 Marginum HIVEN™️ targets glioma operations to improve the quality and workflow of fluorescence-guided surgeries. Visit our updated website!

We’re thrilled to announce that Antti-Pekka Elomaa and Sami Puustinen from the Marginum team have been selected by Mediuutiset Journal as two of the 100 most important influencers in Finnish healthcare! 💡 Elomaa Antti-Pekka MD PhD was awarded in the ‘Health Technology’ category with the following citation: “Neurosurgeon, Adjunct Professor. Responsible for research at the University of Eastern Finland and KUH, developing a hyperspectral imaging-based tool for tissue classification. The microneurosurgical HSI system is the first in Finland and one of the first in Europe. It can identify tissues during brain tumour and cerebrovascular surgery, thus avoiding nearby delicate structures whose damage can lead to paralysis, for example.” Sami Puustinen MD PhD was awarded in the ‘Dissertations of the Year’ category with the following citation: “The doctoral dissertation, built from high-quality publications in a multi-campus collaboration, was interdisciplinary (medicine, computer science, physics) and involved international students (UEF COSI and IMPiT master's programmes); it dealt with the development and application of a theoretical model based on artificial intelligence and optical research equipment during microsurgical treatment. In addition to its scientific and clinical relevance, which has been met with great interest, the work contributes to a growing market in medical photonics.” Congratulations Antti-Pekka & Sami! 🎉

Thank you Slush for the rare opportunity to present Marginum at the Slush 2023 Startup Studio. Our CEO Samu Lehtonen joined the stage to discuss how Marginum’s tissue monitoring solution enables surgeons to perform more accurate and targeted cancer resections, reducing the likelihood of tumour recurrence and the need for reoperations. 🎯 See you at Slush next year! ⚡️ © Petri Anttila

⚡️Exciting news – Speaking at Slush 2023 Startup Studio⚡️ We’re thrilled to announce that Marginum has been chosen to present at Slush Startup Studio, one of the most prestigious tech and startup events globally. 🌐✨ Join CEO Samu Lehtonen on December 1st at 3:51 PM on the Slush Startup Studio stage to learn how Marginum aims to radically improve surgical outcomes and enable a data-driven shift in surgical approach! 💡 Slush 2023, the annual tech event held in Helsinki, Finland, is a celebration of entrepreneurial grit and building to last. Building an enduring company, reaching a technological breakthrough, changing the world – all of the above are born out of persistence. The Startup Studio is the epicentre of innovation – showcasing the top 2% of founders at the event. See you at Slush! 🚀

🚀  Marginum is thrilled to announce a significant milestone. We’ve raised €1.7 million in seed funding from Almaral, Nostetta Ventures, Redstone and Business Finland for market entry of our tissue sensing technology. This investment will enable us to further develop our surgical tissue monitoring solution, enhance our product offerings, acquire CE marking and substantially accelerate our market entry. Marginum’s technique allows precise and quantitative tumour detection without compromising workflows, enabling an informed and data-driven shift in surgical approach. We’re privileged to work together with our collaborators, strategic advisors and investors to improve the outcome and cost-effectiveness of cancer surgery and to fulfil our vision of radically improving surgical outcomes and patient welfare. 🙌 Link to our press release: https://lnkd.in/d4z2f-4Z